Global Influenza Diagnostics Market, By Product (Test Kits, Instruments), Test (Traditional Diagnostic Test, Molecular Diagnostic Tests and Other Molecular Test), Type (Type A Flu, Type B Flu and Type C Flu), Molecular (PCR, INAAT- NASBAT, TMABAS), End-Use (Hospitals, Clinical Laboratories, Research and Academic Institutes and Contract Research Organizations) – Industry Trends and Forecast to 2029.
Influenza Diagnostics Market Analysis and Size
According to the World Health Organization (WHO) studies, seasonal influenza result in around 3 - 5 million cases of severe illness across the globe every year. Rapid diagnostic testing for influenza is a molecular assay that operates more quickly than usual and provides high accuracy, high sensitivity, and high specificity. The simplicity of use, speed of results, high accuracy, and specificity of the results all contribute to the continued reliability of RIDT as a tool for influenza diagnostics, which explains the rise in its use in clinical decision-making for diagnosis and treatment.
Data Bridge Market Research analyses that the influenza diagnostics market which was USD 0.75 billion in 2021, is expected to reach USD 1.26 billion by 2029, at a CAGR of 6.69% during the forecast period 2022 to 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Influenza Diagnostics Market Scope and Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Product (Test Kits, Instruments), Test (Traditional Diagnostic Test, Molecular Diagonostic Tests and Other Molecular Test), Type (Type A Flu, Type B Flu and Type C Flu), End-Use (Hospitals, Clinical Laboratories, Research and Academic Institutes and Contract Research Organizations)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Market Players Covered
Siemens (Germany), Hologic, Inc. (U.S.), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), Abbott (U.S.), BD (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Koninklijke Philips N.V. (Netherlands), NeuroLogica Corp. (U.S.), Shimadzu Medical (India) pvt. Ltd. (Japan), General Electric (U.S.), Quest Diagnostics Incorporated (U.S.), Sysmex India Pvt. Ltd. (Japan), Hitachi, Ltd. (Japan), Canon Inc. (Japan), FUJIFILM Holdings Corporation (U.K.), GenMark Diagnostics, Inc. (U.S.), Luminex Corporation (U.S.), Tecan Trading AG (Switzerland), DiaSorin SA (Italy), altona Diagnostics GmbH (Germany), Sekisui Diagnostics (U.S.)
Influenza is a severe viral respiratory infection that causes significant morbidity and mortality throughout the world. Human disease is caused by three types of influenza, because of its high susceptibility to antigenic variation, influenza A is the type most responsible for pandemics. Influenza is highly contagious, with symptoms including fever, cough, chills or sweats, myalgias, and malaise.
Global Influenza Diagnostics Market Dynamics
- Growth in influenza research for diagnostic technologies
The increasing global prevalence of influenza has increased R&D efforts toward effective detection and diagnosis. The majority of research activity is directed toward developing faster and more accurate diagnostic solutions for influenza viruses, which will lead to market growth.
Furthermore, in the forecast period of 2022–2029, a number of factors are expected to contribute to the growth of the market for influenza diagnostics including the increasing number of government initiatives taken to combat influenza outbreaks, the growing geriatric population worldwide, the advancement of advanced technology, and the rise in cardiovascular diseases and diabetes. The market for influenza diagnostics will expand over the forecast period as a result of increasing healthcare spending, rising research and development, and a number of other favourable factors.
- Advancements in genomic and proteomic technologies
The human genome project and advances in molecular and biomedical technologies have resulted in the development of a plethora of assays and technologies useful for the diagnosis and management of influenza infections. These new technologies, which are based on genomic techniques (such as PCR) and proteomics (such as microarray detection), aid in the discovery of new influenza viruses. They also allow for better surveillance and rapid diagnosis of infectious diseases, which presents a market opportunity.
- Rise in prevalence of influenza
The global market for influenza diagnostics is anticipated to grow as influenza prevalence rises. The centers for disease control and prevention (CDC) predicts that influenza causes somewhere between 12,000 and 79,000 fatalities annually in the United States. The market is also anticipated to develop throughout the forecast period as awareness of the value of early identification and prevention of diseases such as influenza increases.
- Increase in the number of research and development activities
The increasing R&D spending will boost the global adoption rates of these diagnostic tests by providing technologically sophisticated solutions to identify influenza. The widespread use of quick influenza diagnostic testing and the rising influenza prevalence will drive the market revenue for these tests in the upcoming years.
- Unskilled professionals
On the other hand, the lack of skilled and professional personal along with unstable regulatory framework of new diagnostic test approval will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the market.
This influenza diagnostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the influenza diagnostics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on the Influenza Diagnostics Market
Recently, the problem has become more urgent due to the COVID-19 epidemic. Flu testing has increased dramatically across the US. Patients continue to report mixing up the flu with COVID-19 since both of these first symptoms are similar. However, the sequential intervals and related fatality rates of the two viruses are different. Rapid influenza diagnostic testing has increased along with COVID-19 tests due to the epidemic.
- In May 2022, The American pharmaceutical company announced that it had received approval from the USFDA for the drug Aptima CMV Quant Assay for human cytomegalovirus. Use. And this could be a significant step forward in reducing the virus's negative impact on humans.
- In February 2022, Siemens Healthineers, in collaboration with the United Nations Children's Fund, today announced its contribution to strengthening health systems in various African regions by improving access to diagnostics and the link to treatment of major diseases.
Global Influenza Diagnostics Market Scope
The influenza diagnostics market is segmented on the basis of product, test, type and end-use. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Test Kits
- Traditional Diagnostic Test
- Rapid influenza detection tests
- Serological assays
- Direct fluorescent antibodies
- Viral culture
- H1N1 influenza A virus identification kits
- Molecular Diagnostic Tests
- Polymerase Chain Reaction
- Isothermal Nucleic Acid Amplification Tests
- Transcription-Mediated Amplification-Based Assay
- Loop-Mediated Isothermal Amplification-Based Assay
- Nucleic Acid Sequence-Based Amplification Tests
- Other Isothermal Nucleic Acid Amplification Tests
- Other Molecular Tests
- Type A Flu
- Type B Flu
- Type C Flu
- Clinical Laboratories
- Research and Academic Institutes
- Contract Research Organizations
Influenza Diagnostics Market Regional Analysis/Insights
The influenza diagnostics market is analysed and market size insights and trends are provided by country, product, test, type and end-use as referenced above.
The countries covered in the influenza diagnostics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the influenza diagnostics market due to the increasing prevalence of influenza diagnostics, increased R&D efforts towards its effective detection and diagnosis during the forecast period.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to increasing prevalence of influenza among the geriatric population and advanced healthcare facilities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The influenza diagnostics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for influenza diagnostics market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the influenza diagnostics market. The data is available for historic period 2010-2020.
Competitive Landscape and Influenza Diagnostics Market Share Analysis
The influenza diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to influenza diagnostics market.
Some of the major players operating in the influenza diagnostics market are:
- Siemens (Germany)
- Hologic, Inc. (U.S.)
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
- Abbott (U.S.)
- BD (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Thermo Fisher Scientific Inc. (U.S.)
- Koninklijke Philips N.V. (Netherlands)
- NeuroLogica Corp.(U.S.)
- Shimadzu Medical (India) pvt. Ltd. (Japan)
- GENERAL ELECTRIC (U.S.)
- Quest Diagnostics Incorporated (U.S.)
- Sysmex India Pvt. Ltd. (Japan)
- Hitachi, Ltd. (Japan)
- Canon Inc. (Japan)
- FUJIFILM Holdings Corporation (U.K.)
- GenMark Diagnostics, Inc. (U.S.)
- Luminex Corporation (U.S.)
- Tecan Trading AG (Switzerland)
- DiaSorin SA (Italy)
- altona Diagnostics GmbH (Germany)
- Sekisui Diagnostics (U.S.)